Neuroendocrine carcinoma therapeutics to see strong growth to 2017
The global neuroendocrine carcinoma therapeutics market was worth $91 million in 2010, and is forecast to grow at Compound Annual Growth Rate (CAGR) of 27.3% over the next seven years, to value $492 million by 2017, says a new report from GlobalData.
The high growth is primarily attributed to the advent of approved drugs Sutent (sunitinib), Afinitor (everolimus) from 2011 onwards in both the US and Europe and the promising drugs Avastin (bevacizumab) for gastrointestinal (GI) carcinoids and pancreatic neuroendocrine tumors (NETs), pasireotide (SOM 230) and Somatuline Autogel/Depot only for GI carcinoids NETs which are expected to be launched in 2015. These factors will accelerate the growth of the neuroendocrine carcinoma therapeutics market.
High unmet needs exist in the market sector
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze